{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:10:34Z","timestamp":1790161834208,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1124\/jpet.117.242784","type":"journal-article","created":{"date-parts":[[2017,9,28]],"date-time":"2017-09-28T00:30:26Z","timestamp":1506558626000},"page":"377-393","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Preclinical Characterization of (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one (BMS-986169), a Novel, Intravenous, Glutamate N-Methyl-D-Aspartate 2B Receptor Negative Allosteric Modulator with Potential in Major Depressive Disorder"],"prefix":"10.1016","volume":"363","author":[{"given":"Linda J.","family":"Bristow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti","family":"Gulia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Weed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettadapura N.","family":"Srikumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Wen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Graef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pattipati S.","family":"Naidu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charulatha","family":"Sanmathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayant","family":"Aher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanmaya","family":"Bastia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Paschapur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narasimharaju","family":"Kalidindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuchibhotla Vijaya","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thaddeus","family":"Molski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick","family":"Pieschl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alda","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Digavalli V.","family":"Sivarao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Newberry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bookbinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Polino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Keavy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Newton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Shields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Simmermacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Kempson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja Reddy","family":"Kallem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenakshee","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjunath","family":"Ramarao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reeba K.","family":"Vikramadithyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivasan","family":"Thangathirupathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayakumar","family":"Warrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imadul","family":"Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne J.","family":"Bronson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Macor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlie F.","family":"Albright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalton","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorin A.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence R.","family":"Marcin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.117.242784_bib1","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1177\/0091270009336735","article-title":"Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson\u2019s disease","volume":"49","author":"Addy","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/jpet.117.242784_bib2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol Psychiatry"},{"key":"10.1124\/jpet.117.242784_bib3","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1016\/j.bmcl.2011.03.117","article-title":"2,6-Disubstituted pyrazines and related analogs as NR2B site antagonists of the NMDA receptor with anti-depressant activity","volume":"21","author":"Brown","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1124\/jpet.117.242784_bib4","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/npp.2012.246","article-title":"GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects","volume":"38","author":"Burgdorf","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.117.242784_bib5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0893-133X(98)00050-5","article-title":"Long-lasting psychotomimetic consequences of repeated low-dose amphetamine exposure in rhesus monkeys","volume":"20","author":"Castner","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.117.242784_bib6","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1124\/jpet.110.173880","article-title":"Awake rat pharmacological magnetic resonance imaging as a translational pharmacodynamic biomarker: metabotropic glutamate 2\/3 agonist modulation of ketamine-induced blood oxygenation level dependence signals","volume":"336","author":"Chin","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.117.242784_bib7","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.neubiorev.2005.03.017","article-title":"Recent advances in animal models of chronic antidepressant effects: the novelty-induced hypophagia test","volume":"29","author":"Dulawa","year":"2005","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1124\/jpet.117.242784_bib8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1177\/1359786806064325","article-title":"Pharmacological approaches to the treatment of residual symptoms","volume":"20","author":"Fava","year":"2006","journal-title":"J Psychopharmacol"},{"key":"10.1124\/jpet.117.242784_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2015.08.044","article-title":"Inhibition of in vivo [(3)H]MK-801 binding by NMDA receptor open channel blockers and GluN2B antagonists in rats and mice","volume":"766","author":"Fernandes","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.117.242784_bib10","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1176\/ps.2009.60.11.1439","article-title":"What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression","volume":"60","author":"Gaynes","year":"2009","journal-title":"Psychiatr Serv"},{"key":"10.1124\/jpet.117.242784_bib11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.brainres.2015.03.019","article-title":"Effect of acute NR2B antagonist treatment on long-term potentiation in the rat hippocampus","volume":"1609","author":"Graef","year":"2015","journal-title":"Brain Res"},{"key":"10.1124\/jpet.117.242784_bib12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jneumeth.2012.10.009","article-title":"Slice XVIvo\u2122: a novel electrophysiology system with the capability for 16 independent brain slice recordings","volume":"212","author":"Graef","year":"2013","journal-title":"J Neurosci Methods"},{"key":"10.1124\/jpet.117.242784_bib13","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4088\/JCP.14m09298","article-title":"The economic burden of adults with major depressive disorder in the United States (2005 and 2010)","volume":"76","author":"Greenberg","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"10.1124\/jpet.117.242784_bib14","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.neuron.2014.01.035","article-title":"Distinct functional and pharmacological properties of triheteromeric GluN1\/GluN2A\/GluN2B NMDA receptors","volume":"81","author":"Hansen","year":"2014","journal-title":"Neuron"},{"key":"10.1124\/jpet.117.242784_bib15","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/JCP.0b013e31825d70d6","article-title":"A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder","volume":"32","author":"Ibrahim","year":"2012","journal-title":"J Clin Psychopharmacol"},{"key":"10.1124\/jpet.117.242784_bib16","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.bbr.2012.08.016","article-title":"Acute and sustained effects of a metabotropic glutamate 5 receptor antagonist in the novelty-suppressed feeding test","volume":"235","author":"Iijima","year":"2012","journal-title":"Behav Brain Res"},{"key":"10.1124\/jpet.117.242784_bib17","doi-asserted-by":"crossref","first-page":"e0152729","DOI":"10.1371\/journal.pone.0152729","article-title":"The qEEG signature of selective NMDA NR2B negative allosteric modulators; a potential translational biomarker for drug development","volume":"11","author":"Keavy","year":"2016","journal-title":"PLoS One"},{"key":"10.1124\/jpet.117.242784_bib18","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bbr.2015.03.023","article-title":"NMDA receptor subunits and associated signaling molecules mediating antidepressant-related effects of NMDA-GluN2B antagonism","volume":"287","author":"Kiselycznyk","year":"2015","journal-title":"Behav Brain Res"},{"key":"10.1124\/jpet.117.242784_bib19","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2174\/156802606776894447","article-title":"Recent advances in the development of NR2B subtype-selective NMDA receptor antagonists","volume":"6","author":"Layton","year":"2006","journal-title":"Curr Top Med Chem"},{"key":"10.1124\/jpet.117.242784_bib20","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1021\/cn200013d","article-title":"Discovery of 3-substituted aminocyclopentanes as potent and orally bioavailable NR2B subtype-selective NMDA antagonists","volume":"2","author":"Layton","year":"2011","journal-title":"ACS Chem Neurosci"},{"key":"10.1124\/jpet.117.242784_bib21","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s40265-017-0702-8","article-title":"Ketamine and beyond: Investigations into the potential of glutamatergic agents to treat depression","volume":"77","author":"Lener","year":"2017","journal-title":"Drugs"},{"key":"10.1124\/jpet.117.242784_bib22","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1190287","article-title":"mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists","volume":"329","author":"Li","year":"2010","journal-title":"Science"},{"key":"10.1124\/jpet.117.242784_bib23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejphar.2013.06.028","article-title":"Comparison of the ex vivo receptor occupancy profile of ketamine to several NMDA receptor antagonists in mouse hippocampus","volume":"715","author":"Lord","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.117.242784_bib24","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.biopsych.2007.05.028","article-title":"Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors","volume":"63","author":"Maeng","year":"2008","journal-title":"Biol Psychiatry"},{"key":"10.1124\/jpet.117.242784_bib25","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1124\/jpet.103.056291","article-title":"Identification of critical residues in the amino terminal domain of the human NR2B subunit involved in the RO 25-6981 binding pocket","volume":"307","author":"Malherbe","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.117.242784_bib26","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/JCP.0b013e31820ebd2c","article-title":"Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication","volume":"31","author":"McClintock","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"10.1124\/jpet.117.242784_bib27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.neuropharm.2015.07.028","article-title":"Two cellular hypotheses explaining the initiation of ketamine\u2019s antidepressant actions: direct inhibition and disinhibition","volume":"100","author":"Miller","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.117.242784_bib28","doi-asserted-by":"crossref","first-page":"e03581","DOI":"10.7554\/eLife.03581","article-title":"GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine","volume":"3","author":"Miller","year":"2014","journal-title":"eLife"},{"key":"10.1124\/jpet.117.242784_bib29","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/j.1476-5381.2009.00304.x","article-title":"Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential","volume":"157","author":"Mony","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.117.242784_bib30","doi-asserted-by":"crossref","first-page":"5795","DOI":"10.1016\/j.bmcl.2011.07.119","article-title":"Synthesis of a series of \u03b3-amino alcohols comprising an N-methyl isoindoline moiety and their evaluation as NMDA receptor antagonists","volume":"21","author":"M\u00fcller","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1124\/jpet.117.242784_bib31","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0014-2999(00)00263-6","article-title":"Modulation of [3H]MK-801 binding to NMDA receptors in vivo and in vitro","volume":"397","author":"Murray","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.117.242784_bib32","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nrd.2017.16","article-title":"Targeting glutamate signalling in depression: progress and prospects","volume":"16","author":"Murrough","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/jpet.117.242784_bib33","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1046\/j.1471-4159.1998.70052147.x","article-title":"In vitro binding properties in rat brain of [3H]Ro 25-6981, a potent and selective antagonist of NMDA receptors containing NR2B subunits","volume":"70","author":"Mutel","year":"1998","journal-title":"J Neurochem"},{"key":"10.1124\/jpet.117.242784_bib34","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1038\/npp.2015.298","article-title":"Differential effects of an NR2B NAM and ketamine on synaptic potentiation and gamma synchrony: relevance to rapid-onset antidepressant efficacy","volume":"41","author":"Nagy","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.117.242784_bib35","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1756-6606-1-16","article-title":"Structural insights into phenylethanolamines high-affinity binding site in NR2B from binding and molecular modeling studies","volume":"1","author":"Ng","year":"2008","journal-title":"Mol Brain"},{"key":"10.1124\/jpet.117.242784_bib36","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1017\/S0033291700033146","article-title":"Residual symptoms after partial remission: an important outcome in depression","volume":"25","author":"Paykel","year":"1995","journal-title":"Psychol Med"},{"key":"10.1124\/jpet.117.242784_bib37","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.biopsych.2013.01.021","article-title":"Glutamate-based antidepressants: preclinical psychopharmacology","volume":"73","author":"Pilc","year":"2013","journal-title":"Biol Psychiatry"},{"key":"10.1124\/jpet.117.242784_bib38","doi-asserted-by":"crossref","first-page":"634","DOI":"10.12688\/f1000research.8236.1","article-title":"In search of the mechanisms of ketamine\u2019s antidepressant effects: how robust is the evidence behind the mTOR activation hypothesis?","volume":"5","author":"Popp","year":"2016","journal-title":"F1000 Res"},{"key":"10.1124\/jpet.117.242784_bib39","first-page":"327","article-title":"Behavioral despair in mice: a primary screening test for antidepressants","volume":"229","author":"Porsolt","year":"1977","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"10.1124\/jpet.117.242784_bib40","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/JCP.0b013e31818a6cea","article-title":"An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder","volume":"28","author":"Preskorn","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"10.1124\/jpet.117.242784_bib41","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/mp.2017.36","article-title":"Identifying fast-onset antidepressants using rodent models","volume":"22","author":"Ramaker","year":"2017","journal-title":"Mol Psychiatry"},{"key":"10.1124\/jpet.117.242784_bib42","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/FBP.0000000000000266","article-title":"Investigation of antidepressant-like and anxiolytic-like actions and cognitive and motor side effects of four N-methyl-D-aspartate receptor antagonists in mice","volume":"28","author":"Refsgaard","year":"2017","journal-title":"Behav Pharmacol"},{"key":"10.1124\/jpet.117.242784_bib43","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1021\/jm400346a","article-title":"Development of 2\ua78c-substituted (2S,1\ua78cR,2\ua78cS)-2-(carboxycyclopropyl)glycine analogues as potent N-methyl-d-aspartic acid receptor agonists","volume":"56","author":"Risgaard","year":"2013","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.117.242784_bib44","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/WNR.0b013e3283381a4e","article-title":"Glycine transporter inhibition reverses ketamine-induced working memory deficits","volume":"21","author":"Roberts","year":"2010","journal-title":"Neuroreport"},{"key":"10.1124\/jpet.117.242784_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0014-2999(90)90204-J","article-title":"Functional antagonists at the NMDA receptor complex exhibit antidepressant actions","volume":"185","author":"Trullas","year":"1990","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.117.242784_bib46","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1192\/bjp.184.5.386","article-title":"Global burden of depressive disorders in the year 2000","volume":"184","author":"Ust\u00fcn","year":"2004","journal-title":"Br J Psychiatry"},{"key":"10.1124\/jpet.117.242784_bib47","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s12264-014-1504-6","article-title":"Contribution of NMDA receptors to dorsolateral prefrontal cortical networks in primates","volume":"31","author":"Wang","year":"2015","journal-title":"Neurosci Bull"},{"key":"10.1124\/jpet.117.242784_bib48","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.neuron.2012.12.032","article-title":"NMDA receptors subserve persistent neuronal firing during working memory in dorsolateral prefrontal cortex","volume":"77","author":"Wang","year":"2013","journal-title":"Neuron"},{"key":"10.1124\/jpet.117.242784_bib49","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/npp.2015.184","article-title":"Negative allosteric modulators selective for the NR2B subtype of the NMDA receptor impair cognition in multiple domains","volume":"41","author":"Weed","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.117.242784_bib50","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0926-6410(99)00020-8","article-title":"Performance norms for a rhesus monkey neuropsychological testing battery: acquisition and long-term performance","volume":"8","author":"Weed","year":"1999","journal-title":"Brain Res Cogn Brain Res"},{"key":"10.1124\/jpet.117.242784_bib51","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2174\/1570159X14666160309114549","article-title":"Molecular and cellular mechanisms of rapid-acting antidepressants ketamine and scopolamine","volume":"15","author":"Wohleb","year":"2017","journal-title":"Curr Neuropharmacol"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652427141X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652427141X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.117.242784","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T20:08:06Z","timestamp":1739995686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235652427141X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S002235652427141X"],"URL":"https:\/\/doi.org\/10.1124\/jpet.117.242784","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical Characterization of (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one (BMS-986169), a Novel, Intravenous, Glutamate N-Methyl-D-Aspartate 2B Receptor Negative Allosteric Modulator with Potential in Major Depressive Disorder","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.117.242784","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}